A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Rheumatoid arthritis of >/= 6 months duration (according to ACR criteria)

- Inadequate response due to inefficacy of treatment (for at least 3 months) with only
one approved TNF-agent other than adalimumab. Depending on the TNF-inhibitor, last
dose of TNF-inhibitor should have been 1 to 8 weeks before randomization to the study

- On methotrexate treatment for >/=12 weeks immediately prior to baseline, with stable
dose (10-25 mg/week) for the last 8 weeks

- Disease Activity Score (DAS28) >3.2 at baseline

- Oral corticosteroids ( anti-inflammatory drugs (NSAIDs) are permitted if the dose has been stable for >/=6
weeks prior to baseline

Exclusion Criteria:

- Major surgery (including joint surgery) within 8 weeks prior to screening or planned
surgery within 6 months following randomization

- Rheumatic autoimmune disease other than rheumatoid arthritis

- Prior history of or current inflammatory joint disease other than rheumatoid
arthritis

- Functional class IV (ACR criteria)

- History of severe allergic reaction to human, humanized or murine monoclonal
antibodies

- Known active current or history of recurrent infection (including tuberculosis)

- Primary or secondary immunodeficiency (history of or currently active)

- Body weight >150 kg

- Previous treatment with any cell-depleting therapies

- Previous treatment with tocilizumab

- Intra-articular or parenteral corticosteroids within 6 weeks prior to baseline